{
  "relevance_rule": {},
  "priority_rules": [
    {
      "priority": "High",
      "rule_text": "Osimertinib, Tagrisso, Savolitinib, Datopotamab deruxtecan, Dato-DXd, Datroway, HER3-DXd, patritumab deruxtecan, TROP2 (and ADC), HER3, EGFR Bispecifics, Sunvozertinib, Zipalertinib, Firmonertinib, Furmonertinib, Ivonescimab, Sac-TMT, sacituzumab tirumotecan, MK-2870, SKB-264, SKB264, MCLA-129 or pamvatami, AZD-9592 or AZD9592 or tilatamig samrotecan, BL-B01D1 or izalontamab brengitecan, SI-B-001 or izalontamab",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "Osimertinib",
          "Tagrisso",
          "Savolitinib",
          "Datopotamab deruxtecan",
          "Dato-DXd",
          "Datroway",
          "HER3-DXd",
          "patritumab deruxtecan",
          "TROP2",
          "ADC",
          "HER3",
          "EGFR Bispecifics",
          "Sunvozertinib",
          "Zipalertinib",
          "Firmonertinib",
          "Furmonertinib",
          "Ivonescimab",
          "Sac-TMT",
          "sacituzumab tirumotecan",
          "MK-2870",
          "SKB-264",
          "SKB264",
          "MCLA-129",
          "pamvatami",
          "AZD-9592",
          "AZD9592",
          "tilatamig samrotecan",
          "BL-B01D1",
          "izalontamab brengitecan",
          "SI-B-001",
          "izalontamab"
        ],
        "categories": [],
        "contextual_concepts": []
      },
      "exclusions": [
        "4th-Gen EGFR TKIs",
        "ALK",
        "ROS1",
        "KRAS-G12C",
        "NSCLC",
        "SCLC",
        "Antibody Drug Conjugate"
      ],
      "reasoning": "This rule is a priority assignment rule using keywords. All terms are specific drug names or targets, matching client keywords. Exclusions are added to ensure mutual exclusivity with the Medium priority rule."
    },
    {
      "priority": "Medium",
      "rule_text": "4th-Gen (fourth-gen) EGFR TKIs, ALK, ROS1, KRAS-G12C and NSCLC, any ADC for lung (NSCLC or SCLC)",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "4th-Gen EGFR TKIs",
          "fourth-gen EGFR TKIs",
          "ALK",
          "ROS1",
          "KRAS-G12C",
          "NSCLC",
          "SCLC",
          "Antibody Drug Conjugate",
          "ADC"
        ],
        "categories": [
          "Non-Small Cell Lung Cancer",
          "Small-Cell Lung Cancer"
        ],
        "contextual_concepts": []
      },
      "exclusions": [
        "Osimertinib",
        "Tagrisso",
        "Savolitinib",
        "Datopotamab deruxtecan",
        "Dato-DXd",
        "Datroway",
        "HER3-DXd",
        "patritumab deruxtecan",
        "TROP2",
        "HER3",
        "EGFR Bispecifics",
        "Sunvozertinib",
        "Zipalertinib",
        "Firmonertinib",
        "Furmonertinib",
        "Ivonescimab",
        "Sac-TMT",
        "sacituzumab tirumotecan",
        "MK-2870",
        "SKB-264",
        "SKB264",
        "MCLA-129",
        "pamvatami",
        "AZD-9592",
        "AZD9592",
        "tilatamig samrotecan",
        "BL-B01D1",
        "izalontamab brengitecan",
        "SI-B-001",
        "izalontamab"
      ],
      "reasoning": "This rule is a priority assignment rule using keywords. All terms are specific targets, mutations, or cancer types, matching client keywords. Exclusions are added to ensure mutual exclusivity with the High priority rule."
    }
  ]
}